Capillary rarefaction in advanced chronic kidney disease is associated with high phosphorus and bicarbonate levels

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3529-3536

  Thang, Oanh H D ^a,b   Serné, Erik H ^b,c   Grooteman, Muriel P C ^a,b   Smulders, Yvo M ^b,c   Ter Wee, Piet M ^a,b   Tangelder, Geert Jan ^b,c   Nubé, Menso J ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

bicarbonate; capillary density; capillary rarefaction; chronic kidney disease; microcirculation; phosphorus

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM ANTAGONIST; CALCIUM CARBONATE; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER;

ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD SAMPLING; CAPILLARY DENSITY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPEREMIA; MALE; MICROSCOPY; MINERAL METABOLISM; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SKIN CAPILLARY; VEIN OCCLUSION;

BICARBONATES; CALCIFEDIOL; CALCITRIOL; CAPILLARIES; CASE-CONTROL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; PROGNOSIS; SKIN; VASCULAR DISEASES;

EID: 80155136428     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr089     Document Type: Article

References (48)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
2. Gritters M, Grooteman MP, Schoorl M et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153-159
3. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin Dial 2001; 14: 193-199
4. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
5. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
6. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464
7. Serne EH, de Jongh RT, Eringa EC et al. Microvascular dysfunction: A potential pathophysiological role in the metabolic syndrome. Hypertension 2007; 50: 204-211
8. Levy BI, Schiffrin EL, Mourad JJ et al. Impaired tissue perfusion: A pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008; 118: 968-976
9. Sigrist MK, McIntyre CW. Vascular calcification is associated with impaired microcirculatory function in chronic haemodialysis patients. Nephron Clin Pract 2008; 108: C121-c126
10. Antonios TF, Kaski JC, Hasan KM et al. Rarefaction of skin capillaries in patients with anginal chest pain and normal coronary arteriograms. Eur Heart J 2001; 22: 1144-1148
11. Taylor JE, Belch JJ, Henderson IS et al. Peripheral microcirculatory blood flow in haemodialysis patients treated with erythropoietin. Int Angiol 1996; 15: 33-38
12. Kruger A, Stewart J, Sahityani R et al. Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: Correlation with cardiovascular risk. Kidney Int 2006; 70: 157-164
13. McGuire BJ, Secomb TW. A theoretical model for oxygen transport in skeletal muscle under conditions of high oxygen demand. J Appl Physiol 2001; 91: 2255-2265
14. O'Drobinak DM, Greene AS. Decreases in steady-state muscle performance and vessel density in reduced renal mass hypertensive rats. Am J Physiol 1996; 270: H661-H667
15. Holowatz LA, Thompson-Torgerson CS, Kenney WL. The human cutaneous circulation as a model of generalized microvascular function. J Appl Physiol 2008; 105: 370-372
16. Ijzerman RG, de Jongh RT, Serne EH. Commentary on viewpoint: The human cutaneous circulation as a model of generalized microvascular function. J Appl Physiol 2008; 105: 378
17. Serne EH, Gans RO, ter Maaten JC et al. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension 2001; 38: 238-242
18. Treger R, Pirouz S, Kamangar N et al. Agreement between central venous and arterial blood gas measurements in the intensive care unit. Clin J Am Soc Nephrol 2010; 5: 390-394
19. Ijzerman RG, de Jongh RT, Beijk MA et al. Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest 2003; 33: 536-542
20. de Jongh RT, Serne EH, Ijzerman RG et al. Impaired microvascular function in obesity: Implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004; 109: 2529-2535
21. Nissel R, Fischer DC, Puhlmann A et al. Short-term growth hormone treatment and microcirculation: Effects in patients with chronic kidney disease. Microvasc Res 2009; 78: 246-252
22. Debbabi H, Uzan L, Mourad JJ et al. Increased skin capillary density in treated essential hypertensive patients. Am J Hypertens 2006; 19: 477-483
23. Niizuma S, Takiuchi S, Okada S et al. Decreased coronary flow reserve in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 2324-2328
24. Amann K, Tyralla K. Cardiovascular changes in chronic renal failure-pathogenesis and therapy. Clin Nephrol 2002; 58 (Suppl 1): S62-S72
25. Ix JH, De BI, Peralta CA et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-615
26. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617
27. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
28. Wald R, Sarnak MJ, Tighiouart H et al. Disordered mineral metabolism in hemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008; 52: 531-540
29. Noordzij M, Korevaar JC, Dekker FW et al. Mineral metabolism and mortality in dialysis patients: A reassessment of the K/DOQI guideline. Blood Purif 2008; 26: 231-237
30. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 661-671
31. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-2084
32. Mendoza FJ, Lopez I, Montes de OA et al. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 2008; 73: 407-414
33. Schlieper G, Brandenburg V, Ketteler M et al. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 2009; 5: 539-543
34. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985; 23: 63-67
35. Barreto DV, Barreto FC, Liabeuf S et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1128-1135
36. Watson KE, Abrolat ML, Malone LL et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997; 96: 1755-1760
37. Doherty TM, Tang W, Dascalos S et al. Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation 1997; 96: 1477-1481
38. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95
39. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403
40. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
41. Jean G, Terrat JC, Vanel T et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: Effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23: 3670-3676
42. de Groot K, Bahlmann FH, Sowa J et al. Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004; 66: 641-646
43. Westerweel PE, Hoefer IE, Blankestijn PJ et al. End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. Am J Physiol Renal Physiol 2007; 292: F1132-F1140
44. Kalka C, Masuda H, Takahashi T et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198-1202
45. Schlaeppi JM, Gutzwiller S, Finkenzeller G et al. 1,25-Dihydroxyvitamin D3 induces the expression of vascular endothelial growth factor in osteoblastic cells. Endocr Res 1997; 23: 213-229
46. van der Veldt, de Boer MP, Boven E et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs 2010; 21: 439-446
47. Humar R, Zimmerli L, Battegay E. Angiogenesis and hypertension: An update. J Hum Hypertens 2009; 23: 773-782
48. Li M, Batuman V. Vitamin D: A new hope for chronic kidney disease? Kidney Int 2009; 76: 1219-1221